Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis



Status:Withdrawn
Conditions:Healthy Studies, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:18 - 85
Updated:4/21/2016
Start Date:July 2015
End Date:November 2015

Use our guide to learn which trials are right for you!

The investigators are trying to understand the role of specific genes in the function of
airway surface cells. The investigators know that there are some common genetic markers that
are associated with various lung diseases. However, most people with these genetic markers
never develop any evidence of lung disease, so it is not understand how or if these markers
play a role in disease. Investigators are asking healthy people to provide three (3) tubes
of blood as well as a sample of cells from their nose. Investigators will use the blood
sample to provide genetic information (specifically, presence or absence of alleles known to
be associated with pulmonary fibrosis). Nose cells from individuals with the genetic markers
that investigators are studying will be grown in the the lab to allow investigators to learn
more about how the cells respond to various forms of environmental stress, such as exposure
to cigarette smoke. The goal of this study is to understand how specific genes affect airway
cell function.


Inclusion Criteria:

1. Age greater than 18 years of age

2. Ability to provide informed consent

3. Patent bilateral nares

Exclusion Criteria:

1. Significant nasal or sinus disease precluding nasal brushing

2. A history of or ongoing epistaxis (nose-bleeding)

3. Acute upper respiratory illness

4. Ongoing treatment of respiratory or sinus illness with antibiotics

5. Pregnancy

6. Age less than 18 years

7. Infection with human immunodeficiency virus (HIV) or viral hepatitides (Hepatitis B,
Hepatitis C)

8. Prior volunteer for the same study

9. Known diagnosis of cystic fibrosis or other ciliary disorder (example: primary ciliar
dyskinesia)

10. Treatment with anticoagulants (examples: warfarin/coumadin, low molecular weight
heparins, direct thrombin inhibitors such as dabigatran, anti-platelet agents such as
P2Y12 inhibitors like clopidogrel and prasugrel, aspirin, ticagrelor, or factor Xa
inhibitors such as rivaroxaban)

11. Known thrombocytopenia (example: immune thrombocytopenic purpura)

12. Ongoing chemotherapy

13. Known platelet dysfunction or bleeding diathesis/hemophilia
We found this trial at
1
site
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials